Xencor Surges After Encouraging XmAb819 Kidney Cancer Data and Development Plans

2026-10-26

Investivoq PriceTracker

Xencor (XNCR) is up 20.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears tied to updated Phase 1 data for XmAb819 in advanced clear cell renal cell carcinoma that looked strong enough to support dose selection and a potential path toward later-stage development. Investors also seem to be reacting to management’s plan to discuss a possible accelerated approval strategy with the FDA and to prepare a randomized study.

Details:

Xencor presented updated XmAb819 results at ESMO on October 25, 2026, and selected 400 mcg/kg as its proposed recommended Phase 3 dose for intravenous use.

At an October 1, 2026 data cut, the 400 mcg/kg cohort had 5 confirmed partial responses in 11 efficacy-evaluable patients, with 1 additional unconfirmed partial response and a 6-month progression-free survival estimate of 82%.

The company said the study population was heavily pretreated, with patients previously exposed to checkpoint inhibition and VEGFR-targeted therapy, which may make the response rates stand out more to the market.

Xencor outlined next steps that include discussing a potential accelerated approval pathway in selected advanced ccRCC patient groups and planning a global randomized trial against tivozanib, which could have strengthened confidence in the program’s regulatory path.

Sources:

Xencor, StockAnalysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$XNCR Insider Trading Activity

$XNCR insiders have traded $XNCR stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $XNCR stock by insiders over the last 6 months:

ELLEN FEIGAL sold 6,843 shares for an estimated $89,369

To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

$XNCR Hedge Fund Activity

We have seen 117 institutional investors add shares of $XNCR stock to their portfolio, and 74 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ECOR1 CAPITAL, LLC removed 2,183,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $35,146,300
PRICE T ROWE ASSOCIATES INC /MD/ added 795,989 shares (+51.0%) to their portfolio in Q2 2026, for an estimated $12,815,422
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 707,242 shares (+inf%) to their portfolio in Q2 2026, for an estimated $11,386,596
BLACKROCK, INC. added 615,343 shares (+4.7%) to their portfolio in Q2 2026, for an estimated $9,907,022
DEEP TRACK CAPITAL, LP added 593,551 shares (+inf%) to their portfolio in Q2 2026, for an estimated $9,556,171
BRAIDWELL LP removed 459,166 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $7,392,572
RA CAPITAL MANAGEMENT, L.P. added 377,037 shares (+7.7%) to their portfolio in Q2 2026, for an estimated $6,070,295

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

$XNCR Price Targets

Multiple analysts have issued price targets for $XNCR recently. We have seen 2 analysts offer price targets for $XNCR in the last 6 months, with a median target of $20.5.

Here are some recent targets:

Gregory Renza from Truist Securities set a target price of $27.0 on 07/07/2026
Brian Cheng from JP Morgan set a target price of $14.0 on 05/11/2026

This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.